Collegium Pharmaceutical (COLL) Retained Earnings (2014 - 2026)

Collegium Pharmaceutical's Retained Earnings history runs 13 years deep, the most recent figure standing at -$86.6 million for Q1 2026.

• On a quarterly basis, Retained Earnings rose 46.38% year-over-year to -$86.6 million in Q1 2026; TTM through Mar 2026 was -$86.6 million, a 46.38% increase from a year earlier, with the FY2025 full-year figure at $319000.0, down 99.95% from the prior year.
• Retained Earnings fell to -$86.6 million in Q1 2026 per COLL's latest filing, from $319000.0 in the prior quarter.
• Across five years, Retained Earnings topped out at $590.3 million in Q4 2024 and bottomed at -$285.8 million in Q2 2023.
• The 5-year median for Retained Earnings is -$124000.0 (2024), against an average of $66.5 million.
• Across the five-year window, Retained Earnings jumped 4215978.57% in 2024 and slumped 130208.06% in 2025, its largest moves.
• Year by year, Retained Earnings stood at $538.1 million in 2022, then slumped by 100.0% to $14000.0 in 2023, then soared by 4215978.57% to $590.3 million in 2024, then tumbled by 99.95% to $319000.0 in 2025, then sank by 27257.68% to -$86.6 million in 2026.
• Per Business Quant, the three latest COLL Retained Earnings figures stand at -$86.6 million (Q1 2026), $319000.0 (Q4 2025), and -$118.1 million (Q3 2025).